Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.

S-Warfarin 7-hydroxylation, S-flurbiprofen 4'-hydroxylation, and diclofenac 4'-hydroxylation activities were determined in liver microsomes of 30 humans of which 19 were wild-type (Arg144.Ile359), 8 were heterozygous Cys (Cys144.Ile359), and 3 were heterozygous Leu (Arg144.Leu359) allelic variants of the cytochrome P450 2C9 (CYP2C9) gene. All of the human samples examined contained P450 protein(s) immunoreactive with anti-CYP2C9 antibodies in liver microsomes. Individuals with the Cys144 allele of CYP2C9 had similar, but slightly lower, activities for the oxidations of these substrates than those of wild-type CYP2C9. One of the three human samples heterozygous for the Leu359 allele had very low Vmax and high Km values for the oxidation of three substrates examined, while the other two individuals gave kinetic parameters comparable to those seen in the wild-type and Cys144 CYP2C9. Reverse transcriptase-polymerase chain reaction analysis, however, showed that all of the three human samples with the heterozygous Leu359 variant were found to express both Ile359 and Leu359 variants at relatively similar extents in liver RNA of three humans. These results suggest that the Cys144 variant of CYP2C9 catalyzes the CYP2C9 substrates at rates comparative to, but slightly lower than, those of wild-type CYP2C9, while the Leu359-allelic variant has slower rates for the oxidation of these drug substrates. Activities for the oxidation of these CYP2C9 substrates in humans with heterozygous Leu359 allele is likely to be dependent on the levels of expression of each of the wild- and Leu-variants in the livers. However, one of the humans with a heterozygous Leu allele was found to have very low activities towards the oxidation of CYP2C9 substrates. The basis of this defect in catalytic functions towards CYP2C9 substrates is unknown.

[1]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[2]  H. Yamazaki,et al.  Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes , 1996 .

[3]  J. Miners,et al.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.

[4]  J. Goldstein,et al.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.

[5]  R. Kato,et al.  Cytochrome P-450 human-2 (P-450IIC9) in mephenytoin hydroxylation polymorphism in human livers: differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeasts. , 1991, Journal of Biochemistry (Tokyo).

[6]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. , 1986, The Journal of biological chemistry.

[7]  F. Guengerich,et al.  Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. , 1993, Archives of biochemistry and biophysics.

[8]  F. Guengerich.  Reactions and significance of cytochrome P-450 enzymes. , 1991, The Journal of biological chemistry.

[9]  C Marra,et al.  Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. , 1996, Biochemical pharmacology.

[10]  D. Mansuy,et al.  Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.

[11]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[12]  F. Gonzalez,et al.  The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.

[13]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[14]  Y. Yasukochi,et al.  Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. , 1976, The Journal of biological chemistry.

[15]  T. Iyanagi,et al.  Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles. , 1979, Biochimica et biophysica acta.

[16]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[17]  F. Guengerich,et al.  [16] Production and application of antibodies to rat liver cytochrome P-450 , 1981 .

[18]  M. Lai,et al.  Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. , 1995, Pharmacogenetics.

[19]  F. Guengerich,et al.  Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. , 1982, Biochemistry.

[20]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[21]  R. Böcker,et al.  Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. , 1995, Journal of chromatography. B, Biomedical applications.

[22]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[23]  S. Wrighton,et al.  Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. , 1995, Biochemical pharmacology.

[24]  A. Hayes.  Principles and methods of toxicology , 1982 .

[25]  H. Yamazaki,et al.  Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[26]  S. Waldman,et al.  A mutation in CYP2C9 is responsible for decreased metabolism of losartan , 1996 .

[27]  H. Yamazaki,et al.  Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. , 1997, Pharmacogenetics.

[28]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[29]  H Furuya,et al.  Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. , 1995, Pharmacogenetics.

[30]  D. Mansuy,et al.  Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. , 1993, European journal of biochemistry.

[31]  J. Miners,et al.  Allelic and functional variability of cytochrome P4502C9. , 1997, Pharmacogenetics.

[32]  R. Branch,et al.  Genetic polymorphism of S-mephenytoin hydroxylation. , 1989, Pharmacology & therapeutics.

[33]  H. Yamazaki,et al.  Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. , 1997, Biochemical pharmacology.

[34]  P. Srivastava,et al.  Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. , 1989, Biochemistry.

[35]  L. Wienkers,et al.  Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[36]  T. Kase,et al.  Cloning and characterization of a cDNA encoding bovine mannan-binding protein. , 1997, Gene.

[37]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[38]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[39]  M H Tarbit,et al.  Genetic analysis of the human cytochrome P450 CYP2C9 locus. , 1996, Pharmacogenetics.

[40]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.